

116TH CONGRESS
1ST SESSION

H. R. 990

To amend the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

FEBRUARY 6, 2019

Mr. FLORES introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-
2 tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Hatch-Waxman Integ-
5 rity Act of 2019”.

1 SEC. 2. PREVENTING THE INTER PARTES REVIEW PROCESS

2 FOR CHALLENGING PATENTS FROM DIMIN-

3 ISHING COMPETITION IN THE PHARMA-

4 CEUTICAL INDUSTRY AND WITH RESPECT TO

5 DRUG INNOVATION.

6 (a) BRAND NAME DRUGS.—Section 505(b)(2) of the
7 Federal Food, Drug, and Cosmetic Act (21 U.S.C.
8 355(b)(2)) is amended—

(2) in subparagraph (B), by striking the period at the end and inserting “; and”; and

13 (3) by adding at the end the following:

14 “(C) in each certification required under sub-
15 paragraph (A) with respect to a patent, a certifi-
16 cation that—

17 “(i) neither the applicant nor any party in
18 privity with, related to, or cooperating with the
19 applicant has filed, or will file, a petition to in-
20 stitute inter partes review or post-grant review
21 of that patent under chapter 31 or 32, respec-
22 tively, of title 35, United States Code; and

23 “(ii) in making the certification required
24 under subparagraph (A), the applicant is not
25 relying in whole or in part on any decision
26 issued by the Patent Trial and Appeal Board in

1 an inter partes review or post-grant review
2 under chapter 31 or 32, respectively, of title 35,
3 United States Code.”.

4 (b) GENERIC DRUGS.—Section 505(j)(2)(A) of the
5 Federal Food, Drug, and Cosmetic Act (21 U.S.C.
6 355(j)(2)(A)) is amended—

7 (1) in clause (vii)(IV), by striking “and” at the
8 end;

9 (2) in clause (viii), by striking the period at the
10 end and inserting “; and”;

11 (3) by inserting after clause (viii), as amended
12 by paragraph (2), the following:

13 “(ix) in each certification required under
14 clause (vii) with respect to a patent, a certifi-
15 cation that—

16 “(I) neither the applicant nor any
17 party in privity with, related to, or cooper-
18 ating with the applicant has filed, or will
19 file, a petition to institute inter partes re-
20 view or post-grant review of that patent
21 under chapter 31 or 32, respectively, of
22 title 35, United States Code; and

23 “(II) in making the certification re-
24 quired under clause (vii), the applicant is
25 not relying in whole or in part on any deci-

1 sion issued by the Patent Trial and Appeal
2 Board in an inter partes review or post-
3 grant review under chapter 31 or 32, re-
4 spectively, of title 35, United States
5 Code.”; and

(4) in the flush text following clause (ix), as added by paragraph (3), by striking “(viii)” and inserting “(ix)”.

9 (c) BIOSIMILAR DRUGS; EVALUATION BY THE SEC-
10 RETARY.—Section 351(k) of the Public Health Service Act
11 (42 U.S.C. 262(k)) is amended—

12 (1) in paragraph (2)(A)(iii)—

13 (A) by redesignating subclauses (I) and
14 (II) as items (aa) and (bb), respectively, and
15 adjusting the margins accordingly;

19 “(I) IN GENERAL.—An application”;

20 (C) in subclause (I), as so designated—

21 (i) in item (aa), as so redesignated, by
22 striking “and” at the end;

23 (ii) in item (bb), as so redesignated,
24 by striking the period at the end and in-
25 serting “; and”; and

(iii) by adding at the end the following:

3 “(cc) shall, with respect to a
4 patent described in subparagraph
5 (II), include a certification that
6 neither the applicant nor any
7 party in privity with, related to,
8 or cooperating with the applicant
9 has filed, or will file, a petition to
10 institute inter partes review or
11 post-grant review of the patent
12 under chapter 31 or 32, respec-
13 tively, of title 35, United States
14 Code.”; and

15 (D) by adding at the end the following:

19 “(aa) the patent covers the
20 reference product or a method
21 for using the reference product;
22 and

23 “(bb)(AA) the reference
24 product described in item (aa) is

marked under section 287(a) of title 35, United States Code; or

“(BB) there is otherwise public notice regarding the applicability of the reference product described in item (aa).”;

(2) in paragraph (3)—

(A) in subparagraph (A)(ii), by striking “and” at the end;

(B) in subparagraph (B), by striking the period at the end and inserting “; and”;

(C) by adding at the end the following:

“(C) the Secretary determines that the application fully complies with the requirements under paragraph (2)(A)(iii).”.

16 SEC. 3. PREVENTING THE MANIPULATIVE AND DECEPTIVE
17 USE OF INTER PARTES REVIEW.

18 Section 10(b) of the Securities Exchange Act of 1934

19 (15 U.S.C. 78j(b)) is amended—

20 (1) by inserting “(1)” after “(b)”; and

21 (2) by adding at the end the following:

22 “(2) For purposes of paragraph (1), a person shall

23 be considered to be using a manipulative or deceptive de-

24 vice if—

1 “(A) the person, or an affiliate of the person,
2 files a petition to institute an inter partes review
3 under chapter 31 of title 35, United States Code,
4 with respect to a patent; and

5 “(B) the person, or an affiliate of the person,
6 during the 180-day period beginning on the date
7 that is 90 days before the date on which the person
8 files the petition described in subparagraph (A), en-
9 gages in a short sale of any publicly traded security
10 of the owner of the patent that is the subject of the
11 petition.”.

○